11.71
Precedente Chiudi:
$11.45
Aprire:
$11.54
Volume 24 ore:
9,283
Relative Volume:
0.07
Capitalizzazione di mercato:
$402.29M
Reddito:
$7,000
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-12.60
EPS:
-0.9296
Flusso di cassa netto:
$-18.34M
1 W Prestazione:
+6.19%
1M Prestazione:
-7.45%
6M Prestazione:
-10.33%
1 anno Prestazione:
-18.51%
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BNTC
Benitec Biopharma Inc
|
11.71 | 393.36M | 7,000 | -38.96M | -18.34M | -0.9296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.58 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.53 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
828.13 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
294.94 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
152.26 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
BNTC Stock Price, Quote & Chart | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - Sahm
Benitec Biopharma Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Company Overview - Minichart
Benitec Biopharma Reports Q3 2026 Results: Strong BB-301 Clinical Progress for OPMD, $184.8M in Cash, Upcoming FDA Milestones - Minichart
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Benitec Biopharma (BNTC) Fairly Valued After Q3 FY2026 Earnin - GuruFocus
Benitec Biopharma 3Q Loss/Shr 24c >BNTC - Moomoo
Benitec Biopharma Inc. Q3 2026: Revenue $0 Net loss $(11.9M), EPS $(0.24) — 10-Q Summary - TradingView
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
Benitec Biopharma (NASDAQ: BNTC) raises $100M to fund OPMD gene therapy BB-301 - Stock Titan
Benitec Biopharma Q3 net loss narrows as expenses fall - TradingView
BB-301 data, strong cash position shape Benitec (NASDAQ: BNTC) Q3 2026 - Stock Titan
BRIEF-Benitec Biopharma Q3 Operating Income USD -13.6 Million - TradingView
Evercore ISI initiates Benitec BioPharma stock coverage at outperform By Investing.com - Investing.com Australia
BNTC Initiates Coverage On Benitec Biopharma -- Rating Set to Ou - GuruFocus
Evercore ISI initiates Benitec BioPharma stock coverage at outperform - Investing.com UK
The scenario planning at Benitec (BNTC) | Q1 2026: Earnings Fall ShortSecondary Offering - Newser
The one metric that defines Benitec (BNTC) success (On the Radar) 2026-05-08Put Spread Alert - Newser
Trading the Move, Not the Narrative: (BNTC) Edition - Stock Traders Daily
Benitec Biopharma (BNTC) Expected to Announce Earnings on Wednesday - MarketBeat
Benitec presents OPMD gene therapy data at May conference - Investing.com UK
Benitec presents OPMD gene therapy data at May conference By Investing.com - Investing.com India
Rare swallowing disease study posts 24-month follow-up at gene therapy meeting - Stock Titan
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - ChartMill
Biotech founder behind a $14.6B sale joins Seaport board - Stock Titan
Biotech founder behind $14.6B sale joins Seaport board - Stock Titan
(BNTC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Benitec (BNTC) Stock: Why Analysts Watch It (Breakout Watch) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
Macro Review: How liquid is Benitec Biopharma Inc stock2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Quarterly Earnings: Does Benitec Biopharma Inc meet Warren Buffetts criteria2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Is Benitec Biopharma Inc part of any major index2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Entry Recap: What is the Moat Score of Benitec Biopharma IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Is Benitec (BNTC) Stock Priced Correctly | Price at $10.93, Up 0.05%Short Setup - Newser
(BNTC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ideas Watch: How liquid is Benitec Biopharma Inc stockPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Sectors: Can Benitec Biopharma Inc maintain its current growth rate2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Market Wrap: Is Benitec Biopharma Inc stock a buy or sellQuarterly Market Summary & AI Enhanced Trading Alerts - baoquankhu1.vn
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving Average – Here’s What Happened - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(BNTC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Market Moves: Is Benitec Biopharma Inc forming a double bottom2026 Closing Moves & Verified Short-Term Plans - baoquankhu1.vn
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) FY 2025 loss widens to $37.9M - Stock Titan
Benitec Biopharma | 10-K/A: Annual report (Amendment) - Moomoo
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Benitec Biopharma Inc Azioni (BNTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):